Rosetta Prices IPO Below Previously Lowered Range; miRNA R&D Plans Remain Unchanged

Though it has priced its IPO $0.50 below a previously lowered range, the company has not made any changes to how it plans to spend the proceeds on research and development activities.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.